Melanotan II

MT-II

Sexual Health

CAS

121062-08-6

Molecular Weight

1024

Da

Observational

A synthetic analog of alpha-MSH studied in Phase I/II trials for tanning and sexual arousal. The direct precursor to FDA-approved PT-141. No Phase III completion or regulatory approval, sold on grey markets with a notable safety flag profile.

Injectable · Nasal

Intranasal Suitable

No

Research Compound

Research Quality Score
7 dimensions · 100 points total · Methodology by PeptideClear
How we score →
38/100
Weak Evidence
Study Design
10/25
Sample Size
4/20
Replication
5/20
Journal Impact Factor
8/15
Funding Independence
7/10
Population Diversity
1/5
Researcher h-Index
3/5
Dimension Breakdown
Study DesignQuality of research methodology — RCT, observational, animal, or in vitro
10/ 25
Sample SizeNumber of participants across studies supporting this compound
4/ 20
ReplicationIndependent reproduction of findings by separate research groups
5/ 20
Journal Impact FactorPrestige of journals where primary studies were published
8/ 15
Funding IndependenceDegree to which research was funded independently of industry
7/ 10
Population DiversityDiversity of study participants across age, sex, and ethnicity
1/ 5
Researcher h-IndexCitation credibility of the primary research team
3/ 5
Scored by PeptideClear editorial team · Based on publicly available literature
StrongModerateLimitedWeak

Community Signal

Melanotan II has one of the highest raw community signal volumes in any peptide category, but the signal is polarized in a way that's analytically important. On tanning forums, bodybuilding communities (r/PEDs, various fitness subreddits), and dedicated MT-II threads, the tanning efficacy reports are overwhelming and highly consistent: even fair-skinned users who have never tanned naturally report achieving a deep, lasting tan with loading doses and UV trigger exposure. This is the compound's undisputed community reputation. Sexual arousal effects (spontaneous erections in men, increased libido in women) are also consistently reported and align with the MC4R mechanism. Where the signal fractures is on safety: nausea and flushing at loading doses are near-universal, mole darkening reports are common, and the melanoma case reports that circulate have generated genuine anxiety even among regular users. A visible subset of long-term users has stopped using MT-II specifically due to changing mole concerns. The regulatory pressure (TikTok removal of content, MHRA and TGA warnings, vendor crackdowns) has also driven some community activity underground or to more cautious tone. The gap between MT-II's community efficacy signal on tanning and its institutional risk signal is one of the starkest evidence-versus-anecdote cases in the catalog, the compound appears to do exactly what users report, and the safety concerns are real and unresolved simultaneously.

We break down one compound like this every week

The Honest Dose — free, no sponsorships, no agenda. Just the evidence.

Subscribe free →

What It Is

Melanotan II is a cyclic synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the 1980s–90s as part of a program to create a tanning agent that could reduce UV-induced skin cancer risk. It is the direct precursor molecule from which PT-141 (bremelanotide) was derived, PT-141 was essentially MT-II with the tanning effect deprioritized and the sexual arousal pathway refined. MT-II was never brought to regulatory approval and is now sold as a research chemical or grey-market injectable.

Mechanism of Action

MT-II is a non-selective melanocortin receptor agonist with activity at MC1R (pigmentation), MC3R (energy balance), MC4R (sexual arousal, erectile function), and MC5R (exocrine glands). Its broad receptor profile is both its pharmacological interest and its primary safety liability. MC1R activation drives melanogenesis, increased eumelanin production and skin darkening. MC4R activation in the hypothalamus drives the pro-erectile and pro-arousal effects that were subsequently isolated in the development of PT-141. The non-selectivity means side effects, nausea, facial flushing, spontaneous erections, yawning, are common and mechanistically expected, not idiosyncratic.

Use Cases

Tanning (melanogenesis); sexual dysfunction in men (erectile dysfunction) and women (arousal); studied in Phase I/II for both indications. Community use is predominantly tanning + sexual function combined. Sometimes used by bodybuilders pre-competition for cosmetic tanning.

Known Risks

Nausea and facial flushing are the most commonly reported effects and are dose-dependent. Spontaneous erections (men) are frequent and can be prolonged. Melanocytic nevus darkening and new mole formation have been reported, this is a genuine safety concern given MC1R's role in melanoma pathways. Case reports of mole changes and at least one melanoma case associated with MT-II use exist in the literature. Blood pressure elevation has been documented in Phase I trials. Long-term safety data is absent. Not manufactured under pharmaceutical GMP standards in grey-market supply chains, dosing accuracy and contamination risk are compounding factors.

Available Forms

Melanotan II is not approved for human use anywhere and is not manufactured under pharmaceutical GMP standards through any legal supply chain. It is sold as a lyophilized powder for reconstitution by grey-market peptide vendors. Nasal spray formulations also exist in grey markets but have uncertain bioavailability. It is not available through licensed pharmacies or telehealth providers in the US.

Regulatory Status

Melanotan II has no regulatory approval in the United States, European Union, United Kingdom, or Australia. The FDA has issued multiple warning letters to vendors marketing MT-II. The UK's MHRA and Australia's TGA have both issued safety warnings. It is not on the FDA 503A Bulk List and cannot be legally compounded. It occupies a grey legal area in most jurisdictions, not a scheduled controlled substance in the US but not approved for human use. PT-141 (bremelanotide/Vyleesi) is the FDA-approved successor for sexual dysfunction indications.

Sources

https://pubmed.ncbi.nlm.nih.gov/8709382/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9369360/


Similar Compounds

PT-141, Melanotan I

Enjoyed this profile? Get one compound broken down in depth every week in The Honest Dose.

Join The Honest Dose →